Blog
RSS FeedPosted by Michael Wonder on 05 Sep 2024
Winrevair (sotatercept) is now authorised for use in Canada for adults with pulmonary arterial hypertension
4 September 2024 - Merck announced that Winrevair (sotatercept) is now authorised for use in Canada in combination with standard ...
Posted by Michael Wonder on 04 Sep 2024
Lilly Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Omvoh (mirikizumab) for adults with moderately to severely active ulcerative colitis
3 September 2024 - Eli Lilly Canada announced today that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for Omvoh ...
Posted by Michael Wonder on 28 Aug 2024
Kye Pharmaceuticals announces approval in Canada for ACCRUFeR (ferric maltol) for the treatment of iron deficiency anaemia in adult patients
27 August 2024 - Kye Pharmaceuticals today announced that ACCRUFeR (ferric maltol) has received market authorisation as a prescription medicine in ...
Posted by Michael Wonder on 25 Aug 2024
Padcev (enfortumab vedotin) in combination with pembrolizumab approved by Health Canada to treat advanced bladder cancer
22 August 2024 - Padcev plus pembrolizumab approved based on EV-302 trial. ...
Posted by Michael Wonder on 25 Aug 2024
Henlius trastuzumab receives approval in Canada
22 August 2024 - Shanghai Henlius Biotech announced that the company's business partner, Accord Healthcare has received marketing approval (Notice of ...
Posted by Michael Wonder on 25 Aug 2024
Health Canada approves Keytruda for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer with no prior systemic therapy for metastatic urothelial cancer, in combination with enfortumab vedotin
22 August 2024 - Approval is based on the Phase 3 KEYNOTE-A39 trial. ...
Posted by Michael Wonder on 25 Aug 2024
Lupin receives Health Canada approval for biosimilar pegfilgrastim
23 August 2024 - Lupin today announced that it has received approval from Health Canada for its biosimilar Pegfilgrastim. ...
Posted by Michael Wonder on 16 Aug 2024
First public drug plans provide reimbursement for Camzyos for adults with symptomatic obstructive hypertrophic cardiomyopathy
15 August 2024 - BMS Canada is pleased to announce an important milestone for eligible patients with symptomatic obstructive hypertrophic ...
Posted by Michael Wonder on 15 Aug 2024
Imfinzi granted priority review and breakthrough therapy designation for patients with limited-stage small cell lung cancer in the US
15 August 2024 - Based on ADRIATIC Phase 3 trial which demonstrated statistically significant and clinically meaningful overall survival and ...
Posted by Michael Wonder on 13 Aug 2024
Introducing Jubbonti and Wyost, the first denosumab biosimilars on the Canadian market
12 August 2024 - Jubbonti and Wyost are first denosumab biosimilars available in Canada, reflecting the Sandoz Purpose of pioneering access ...
Posted by Michael Wonder on 09 Aug 2024
Canada’s Drug Agency taking steps to expand access to real world evidence
7 August 2024 - Canada’s Drug Agency has published a summary report from its time-limited Industry Task Force. ...
Posted by Michael Wonder on 04 Aug 2024
First time-limited reimbursement recommendation supports earlier patient access to a promising cancer treatment
30 July 2024 - Patients in Canada with advanced-stage lymphoma are one step closer to accessing the first drug to receive ...
Posted by Michael Wonder on 02 Aug 2024
Marius Pharmaceuticals submits Kyzatrex (testosterone undecanoate) capsules for approval to Health Canada
30 July 2024 - Marius Pharmaceuticals is pleased to announce the submission of its new drug submission for Kyzatrex (testosterone ...
Posted by Michael Wonder on 02 Aug 2024
Nordimet (methotrexate) self-injection pen now available in Canada for treatment of rheumatoid arthritis and psoriasis/psoriatic arthritis
1 August 2024 - Linepharma is pleased to announce that Nordimet (methotrexate), the first methotrexate single-use pre-filled pen for self-injection, ...
Posted by Michael Wonder on 02 Aug 2024
Health Canada approves Celltrion’s Steqeyma, a biosimilar to Stelara (ustekinumab) for the treatment of multiple chronic inflammatory conditions
1 August 2024 - Steqeyma, is now approved in Canada for adult patients with plaque psoriasis as well as adults with ...